
EquitySector - HealthcareVery High Risk
Regular
NAV (13-Apr-26)
Returns (Since Inception)
Fund Size
₹300 Cr
Expense Ratio
2.39%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+4.79%
+7.09% (Cat Avg.)
Since Inception
-5.07%
— (Cat Avg.)
| Equity | ₹284.76 Cr | 94.78% |
| Debt | ₹0.9 Cr | 0.30% |
| Others | ₹14.79 Cr | 4.92% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹28.26 Cr | 9.41% |
| Divi's Laboratories Ltd | Equity | ₹26.9 Cr | 8.95% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹20.29 Cr | 6.75% |
| Aurobindo Pharma Ltd | Equity | ₹19.93 Cr | 6.63% |
| Piramal Pharma Ltd | Equity | ₹17.1 Cr | 5.69% |
| Torrent Pharmaceuticals Ltd | Equity | ₹16.72 Cr | 5.57% |
| Emcure Pharmaceuticals Ltd | Equity | ₹13.08 Cr | 4.35% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹12.21 Cr | 4.06% |
| Rubicon Research Ltd | Equity | ₹11.55 Cr | 3.84% |
| Net Receivables / (Payables) | Cash | ₹10.5 Cr | 3.50% |
| Neuland Laboratories Ltd | Equity | ₹10.27 Cr | 3.42% |
| Fortis Healthcare Ltd | Equity | ₹9.55 Cr | 3.18% |
| Ipca Laboratories Ltd | Equity | ₹8.08 Cr | 2.69% |
| Zydus Wellness Ltd | Equity | ₹7.4 Cr | 2.46% |
| Navin Fluorine International Ltd | Equity | ₹6.16 Cr | 2.05% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹5.96 Cr | 1.98% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹5.91 Cr | 1.97% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹5.43 Cr | 1.81% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹5.32 Cr | 1.77% |
| Shaily Engineering Plastics Ltd | Equity | ₹5.17 Cr | 1.72% |
| Bajaj Finserv Money Market Dir Gr | Mutual Fund - Open End | ₹5.13 Cr | 1.71% |
| Laurus Labs Ltd | Equity | ₹4.96 Cr | 1.65% |
| Godrej Consumer Products Ltd | Equity | ₹4.92 Cr | 1.64% |
| Lupin Ltd | Equity | ₹4.69 Cr | 1.56% |
| Dr. Lal PathLabs Ltd | Equity | ₹4.62 Cr | 1.54% |
| Abbott India Ltd | Equity | ₹4.5 Cr | 1.50% |
| Medplus Health Services Ltd | Equity | ₹4.34 Cr | 1.44% |
| Biocon Ltd | Equity | ₹4.13 Cr | 1.38% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹3.24 Cr | 1.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.11 Cr | 1.03% |
| Medi Assist Healthcare Services Ltd | Equity | ₹2.99 Cr | 0.99% |
| Jubilant Pharmova Ltd | Equity | ₹2.86 Cr | 0.95% |
| Emami Ltd | Equity | ₹2.55 Cr | 0.85% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.54 Cr | 0.84% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹0.07 Cr | 0.02% |
Large Cap Stocks
36.38%
Mid Cap Stocks
22.37%
Small Cap Stocks
36.03%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹258.55 Cr | 86.06% |
| Consumer Defensive | ₹14.87 Cr | 4.95% |
| Basic Materials | ₹11.33 Cr | 3.77% |
Standard Deviation
This fund
--
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better

Since December 2024

Since December 2024

Since December 2024
ISIN INF0QA701987 | Expense Ratio 2.39% | Exit Load 1.00% | Fund Size ₹300 Cr | Age 1 year 3 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹33,148 Cr
Address
8th floor, E-Core,Solitaire Business Hub (formerly Marvel Edge), Viman Nagar 411014
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments